Advances in the field of biotechnology have enabled the development of several minimally invasive / non-invasive approaches for diagnosis of fibrotic diseases which include imaging diagnostics and biomarker-based assays. Among the biomarker-based tests, liquid biopsy (based on the analysis of biofluids such as blood, urine and / or plasma), a relatively new concept, has emerged as a versatile and promising non-invasive method for the detection of not only cancer but also fibrosis. In addition, there are numerous forms of genetic analysis which enable accurate diagnosis of diseases such as cystic fibrosis; these biomarker and genetic tests are backed by clinical data, validating their relevance and applicability across several types of fibrotic indications, and are anticipated to replace the existing invasive diagnostic techniques in the future.
Over the years, various research initiatives in this field have helped medical professionals to understand the mechanism behind fibrosis better. In addition, several technological advancements have been made, which have led to the development of new diagnostic tools. These modern diagnostics can help detect and classify fibrosis with increased efficacy and accuracy.
Once suspected, diagnosis is usually made by pathologists and imaging radiologists. The more accurate the diagnosis, the more effective treatment strategies can be employed. Precise diagnosis and staging of fibrosis are extremely essential for prognosis and progression of the disease.
Fibrosis is a medical condition involving the formation of fibrous connective tissue in response to tissue injury or damage by the natural repair mechanism of our body.
Early detection of fibrosis plays a critical role in facilitating successful treatment of the disease. This condition can be detected in its early stages by timely screening (randomly carried out on large masses) of the patient for deposition of extracellular matrix. In this context, non-invasive methods can play a pivotal role in early diagnosis of such diseases, given that they are biomarker-specific and have a fast turnaround time.
Liver, heart (cardiac), lung (pulmonary) and kidney fibrosis are the most common types of organ fibrosis. Along with these four, there are few other types of fibrosis which occurs as the result of ECM deposition like bone marrow fibrosis, skin fibrosis, cavity fibrosis and systemic sclerosis. Other fibrosis like cystic fibrosis and non-alcoholic steatohepatitis (NASH) are associated with lung and liver fibrosis respectively.
The Evolving landscape of Non-Invasive Diagnostics for Fibrotic Diseases
Even though efforts for development of non-invasive diagnostics for fibrotic have been undertaken by players based all across the globe, majority of the developers are headquartered in North America. Within North America, US has emerged as a prominent region where maximum product developers are located. This is followed by players based in Europe; within this region, majority of the developers are headquartered in France. Further, some of the players are located in Asia Pacific. Further, as more product candidates are approved by regulatory authorities across the globe, the number of clinical trials across different regions is anticipated to increase. To get a detailed information on the key players, recent developments, and the likely market evolution, visit this link